Last updated: February 16, 2026
What Is the Market Position and Price Range for NDC 75907-0084?
NDC 75907-0084 is identified as Trastuzumab-dkst, a biosimilar for Herceptin (trastuzumab), used primarily in HER2-positive breast cancer and gastric cancer treatments. It is marketed by Samsung Bioepis under the brand Ontruzant in the United States.
Market Overview
Regulatory Status and Market Authorization
- FDA Approval: Approved in August 2019.
- Indications: HER2-positive breast cancer, metastatic or early-stage; gastric cancer.
- Patent Landscape: Biosimilar was developed to address patent exclusivity of Herceptin, which costs significantly more.
Market Penetration
- Biological Oncology: One of the most lucrative sectors in oncology biosimilars.
- Market Share: Biosimilars of trastuzumab are gaining in volume, though still account for a now modest share versus originator Herceptin.
- Sales Data: Worldwide sales of trastuzumab (~$7 billion in 2022) create significant opportunities for biosimiars.
Competitive Landscape
- Multiple biosimilars approved and marketed, including:
- Pfizer's Ogivri (trastuzumab-dkst)
- Celltrion’s Herzuma (trastuzumab-pkrb)
- Samsung’s Ontruzant (trastuzumab-dkst)
- Biosimilar adoption varies by region; US markets show slower uptake compared to Europe.
Price Projections
US Price Range
- Average Wholesale Price (AWP): Estimated at $3,500 to $5,200 per 440 mg vial, depending on negotiations and discounts.
- Patient Cost: After insurance and discounts, patient copays typically fall between $300 and $1,200 per dose, depending on insurance coverage.
Market Price Trends
- Biosimilar prices tend to be approximately 15-30% lower than the originator post-launch.
- Over time, price reductions in biosimilar markets are driven by increased competition and healthcare policy adjustments.
Price Trends Forecast (2023–2027)
| Year |
Estimated Average Price per Vial |
Key Factors |
| 2023 |
$3,500 – $4,200 |
Entry phase, initial discounts reflect early market adoption. |
| 2024 |
$3,200 – $3,900 |
Continued price competition among biosimilars. |
| 2025 |
$3,000 – $3,700 |
Market stabilization, generic biosignals grow. |
| 2026 |
$2,800 – $3,500 |
Further price reductions as biosalmers gain market share. |
| 2027 |
$2,600 – $3,200 |
Potential for price plateau, further biosimilar launches. |
Major Price Drivers
- Patent litigations and market exclusivity policies.
- Insurance company negotiations and formulary preferences.
- Uptake in biosimilar prescribing by oncologists.
Key Market Dynamics
Cost Savings and Healthcare Impact
- Biosimilar adoption is projected to reduce trastuzumab-related expenditure by 20-30% over the next five years.
- Larger healthcare systems and payers push for biosimilar usage, incentivized by cost-saving goals.
Barriers to Adoption
- Physician and patient acceptance concern.
- Limited switching policies and prescriber familiarity.
- Regulatory pathways affecting market entry speed.
Regional Variations
- United States: Slower adoption at around 15-20% of trastuzumab prescriptions as of 2022.
- Europe: Greater uptake at over 70% for biosimilars in HER2-positive breast cancer.
Conclusion
NDC 75907-0084, as a biosimilar of trastuzumab, faces a competitive and price-sensitive market. Expect prices to decline gradually over the next five years, driven by increased biosimilar entry and healthcare policy shifts. Market share growth remains contingent on prescriber acceptance, insurer support, and regulatory dynamics.
Key Takeaways
- Biosimilar price per vial likely to decrease from ~$3,500–$4,200 in 2023 to ~$2,600–$3,200 by 2027.
- US market adoption remains gradual; Europe shows higher uptake.
- Cost-saving policies and competitive pressures will influence pricing and market share.
- Overall, biosbirals are set to capture approximately 30-40% of trastuzumab prescriptions over the next five years.
FAQs
1. How does NDC 75907-0084 compare to the original Herceptin in price?
It is estimated to be 15-30% cheaper per dose, providing potential savings, especially at scale.
2. What factors could accelerate its market uptake?
Insurance coverage, prescriber familiarity, and reduced regulatory barriers could increase adoption.
3. How does biosimilar regulation impact pricing?
Stringent biosimilar approval pathways can delay market entry but may lead to more competitive pricing when approved.
4. What are the main challenges hindering biosimilar market penetration?
Physician and patient acceptance, limited switching policies, and payer hesitance.
5. What is the likely future trend for biosimilar pricing?
Gradual decline driven by increasing competition, with stabilization around 2026–2027.
References
- IQVIA. Global Oncology Trends 2022.
- FDA. Biosimilar Approvals and Policies.
- EvaluatePharma. World Market for Biosimilars.
- Centers for Medicare & Medicaid Services. Drug Pricing and Reimbursement.
